Implementation and Evaluation of the SAEM Algorithm for Longitudinal Ordered Categorical Data with an Illustration in Pharmacokinetics–Pharmacodynamics

Analysis of longitudinal ordered categorical efficacy or safety data in clinical trials using mixed models is increasingly performed. However, algorithms available for maximum likelihood estimation using an approximation of the likelihood integral, including LAPLACE approach, may give rise to biased parameter estimates. The SAEM algorithm is an efficient and powerful tool in the analysis of continuous/count mixed models. The aim of this study was to implement and investigate the performance of the SAEM algorithm for longitudinal categorical data. The SAEM algorithm is extended for parameter estimation in ordered categorical mixed models together with an estimation of the Fisher information matrix and the likelihood. We used Monte Carlo simulations using previously published scenarios evaluated with NONMEM. Accuracy and precision in parameter estimation and standard error estimates were assessed in terms of relative bias and root mean square error. This algorithm was illustrated on the simultaneous analysis of pharmacokinetic and discretized efficacy data obtained after a single dose of warfarin in healthy volunteers. The new SAEM algorithm is implemented in MONOLIX 3.1 for discrete mixed models. The analyses show that for parameter estimation, the relative bias is low for both fixed effects and variance components in all models studied. Estimated and empirical standard errors are similar. The warfarin example illustrates how simple and rapid it is to analyze simultaneously continuous and discrete data with MONOLIX 3.1. The SAEM algorithm is extended for analysis of longitudinal categorical data. It provides accurate estimates parameters and standard errors. The estimation is fast and stable.

[1]  Mats O Karlsson,et al.  Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients. , 2003, British journal of clinical pharmacology.

[2]  Mats O. Karlsson,et al.  Performance in population models for count data, part I: maximum likelihood approximations , 2009, Journal of Pharmacokinetics and Pharmacodynamics.

[3]  G. Molenberghs,et al.  Longitudinal data analysis , 2008 .

[4]  R. Miller,et al.  Exposure‐response Analysis for Spontaneously Reported Dizziness in Pregabalin‐treated Patient With Generalized Anxiety Disorder , 2008, Clinical pharmacology and therapeutics.

[5]  Mats O. Karlsson,et al.  Comparison of proportional and differential odds models for mixed-effects analysis of categorical data , 2008, Journal of Pharmacokinetics and Pharmacodynamics.

[6]  R A O'REILLY,et al.  STUDIES ON THE COUMARIN ANTICOAGULANT DRUGS: THE PHARMACODYNAMICS OF WARFARIN IN MAN. , 1963, The Journal of clinical investigation.

[7]  Lewis B. Sheiner,et al.  Simultaneous vs. Sequential Analysis for Population PK/PD Data I: Best-Case Performance , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[8]  Marc Lavielle,et al.  Performance in population models for count data, part II: A new SAEM algorithm , 2009, Journal of Pharmacokinetics and Pharmacodynamics.

[9]  J Whitehead,et al.  A random effects model for ordinal responses from a crossover trial. , 1991, Statistics in medicine.

[10]  Lewis B. Sheiner,et al.  Simultaneous vs. Sequential Analysis for Population PK/PD Data II: Robustness of Methods , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[11]  Matts Kågedal,et al.  Modelling a Spontaneously Reported Side Effect by Use of a Markov Mixed-Effects Model , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[12]  Marc Lavielle,et al.  Maximum likelihood estimation in nonlinear mixed effects models , 2005, Comput. Stat. Data Anal..

[13]  P M Aggeler,et al.  Studies on Coumarin Anticoagulant Drugs: Initiation of Warfarin Therapy Without a Loading Dose , 1968, Circulation.

[14]  Robert J. Bauer,et al.  A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples , 2007, The AAPS Journal.

[15]  M O Karlsson,et al.  Diagnosing Model Diagnostics , 2007, Clinical pharmacology and therapeutics.

[16]  R. Savic,et al.  Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions , 2009, The AAPS Journal.

[17]  D R Stanski,et al.  Population pharmacodynamic model for ketorolac analgesia , 1996, Clinical pharmacology and therapeutics.

[18]  L B Sheiner,et al.  A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data , 1994, Clinical pharmacology and therapeutics.

[19]  Marc Lavielle,et al.  Estimation of Population Pharmacokinetic Parameters of Saquinavir in HIV Patients with the MONOLIX Software , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[20]  Siv Jönsson,et al.  Estimating Bias in Population Parameters for Some Models for Repeated Measures Ordinal Data Using NONMEM and NLMIXED , 2004, Journal of Pharmacokinetics and Pharmacodynamics.

[21]  France Mentré,et al.  Fisher information matrix for nonlinear mixed effects multiple response models: Evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model , 2009, Statistics in medicine.